Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent
Complete the form below to unlock access to ALL audio articles.
The claims cover the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to issue in this patent family.
Dr. Alan Moore, President and CEO, commented as follows: "The technology covered by this patent is of potential use as cell transplant therapy for treating demyelinating diseases resulting from oligodendrocyte loss or damage, such as multiple sclerosis and spinal cord injury. This patent expands and adds value to SCT's overall intellectual property portfolio."